Eli Lilly's Weight-Loss Pill Foundayo Gets First European Approval in UK

Eli Lilly's oral weight-loss pill, orforglipron, sold under the brand name Foundayo, received its first European regulatory approval on Monday from the UK's Medicines and Healthcare products Regulatory Agency (MHRA). The approval covers weight management and type 2 diabetes. This marks a significant step for the pharmaceutical company, as it expands its presence in the weight-loss market. The approval in the UK could pave the way for further approvals in other European countries. The pill offers an oral alternative to injectable weight-loss drugs, potentially increasing accessibility for patients. Eli Lilly's stock ticker is $LLY. The approval was announced on a Monday, though the specific date was not provided in the source. The MHRA is the regulatory body responsible for approving medicines in the UK. This development is part of a broader trend of oral weight-loss treatments gaining regulatory approval.